Detalhe da pesquisa
1.
Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study.
Crit Care
; 22(1): 354, 2018 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30583748
2.
Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.
Gastric Cancer
; 20(2): 358-367, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27255289
3.
Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group).
Invest New Drugs
; 30(3): 1184-92, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21484249
4.
Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD.
J Am Soc Nephrol
; 21(12): 2151-6, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21115615
5.
A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2).
BMJ Open
; 9(2): e024475, 2019 02 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30782906
6.
Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failure.
J Intensive Care
; 4: 24, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27034779
7.
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
J Clin Oncol
; 20(6): 1657-67, 2002 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11896117
8.
Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Clin Cancer Res
; 9(5): 1648-55, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12738717
9.
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
Clin Cancer Res
; 9(15): 5465-76, 2003 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-14654525
10.
Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas.
Am J Ophthalmol
; 136(1): 194-6, 2003 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12834696
11.
Case 2. Hemangioblastomas: diagnosis of von Hippel-Lindau disease and antiangiogenic treatment with SU5416.
J Clin Oncol
; 23(15): 3624-6, 2005 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-15908674
12.
Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
Adv Ther
; 27(12): 941-52, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20972656
13.
Antiangiogenic therapy for von Hippel-Lindau disease.
JAMA
; 291(8): 943-4, 2004 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-14982909
14.
Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Curr Med Res Opin
; 24(3): 625-37, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18208642
15.
Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia.
Curr Med Res Opin
; 24(5): 1407-15, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18394266
16.
A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance.
Invest New Drugs
; 24(4): 299-304, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16237511
17.
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
J Clin Oncol
; 24(1): 25-35, 2006 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16314617
18.
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Blood
; 105(3): 986-93, 2005 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15459012
19.
Recurrence of left ventricular hypertrophy following cessation of erythropoietin therapy.
Artif Organs
; 26(2): 98-102, 2002 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-11879236
20.
Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy.
Blood
; 99(10): 3851-3, 2002 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11986247